Inventor
NEUMANN CHRISTIANE
CH14 patents
⚠️ This page may combine multiple inventors who share the name “NEUMANN CHRISTIANE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
HOFFMANN LA ROCHE
7 patentsUS10611841B2Apr 7, 2020
Bispecific T cell activating antigen binding molecules
HOFFMANN LA ROCHE4 citations84
US10611840B2Apr 7, 2020
Bispecific T cell activating antigen binding molecules
HOFFMANN LA ROCHE4 citations84
US10323099B2Jun 18, 2019
Multispecific domain exchanged common variable light chain antibodies
HOFFMANN LA ROCHE13 citations84
US11117965B2Sep 14, 2021
Bispecific T cell activating antigen binding molecules
HOFFMANN LA ROCHE2 citations73
US12103982B2Oct 1, 2024
T cell activating bispecific antigen binding molecules
HOFFMANN LA ROCHE0 citations62
US10766967B2Sep 8, 2020
Bispecific T cell activating antigen binding molecules
HOFFMANN LA ROCHE1 citations62
US12466889B2Nov 11, 2025
Anti-HLA-G antibodies and use thereof
HOFFMANN LA ROCHE0 citations44
ROCHE GLYCART AG
6 patentsUS10155815B2Dec 18, 2018
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG12 citations83
US10087250B2Oct 2, 2018
Fc-free antibodies comprising two fab-fragments and methods of use
ROCHE GLYCART AG10 citations83
US11459404B2Oct 4, 2022
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG5 citations72
US10781258B2Sep 22, 2020
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG4 citations72
US11639397B2May 2, 2023
Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use
ROCHE GLYCART AG0 citations62
US10781257B2Sep 22, 2020
Bispecific T cell activating antigen binding molecules
ROCHE GLYCART AG1 citations62